综述与专论：CKLF1作为缺血性脑卒中治疗的潜在靶点

缺血性脑卒中是一种血液循环障碍疾病,可导致严重的神经功能缺损。卒中病人中约有87%的病例为缺血性卒中。神经炎症是中风损伤的主要病理状态之一。CKLF1是2001年发现的非经典CC型趋化因子,对单核细胞、中性粒细胞和淋巴细胞表现出很强的趋化活性。CKLF1在胎儿大脑中含量最高,但在健康成人阶段不存在。越来越多的证据表明,CKLF1表达在成年卒中动物模型中,并被重新激活,参与神经炎症反应的多个过程。然而,其生物活性和药物发现的发展仍缺乏系统的文献报道。因此,我们收集已发表的资料并做此综述,简要阐明CKLF1在缺血性脑卒中中的作用,并解释其加重缺血性脑卒中的机制。此外,还发现了一些潜在的抗卒中药物,表明CKLF1是治疗缺血性卒中的潜在靶点。     

中药通过调节小胶质细胞激活改善缺血性脑卒中

炎症反应是造成脑卒中继发性脑损伤的关键因素之一。小胶质细胞作为脑内免疫细胞,在脑卒中的炎症反应具有重要作用。传统观念认为小胶质细胞促进炎症反应加重脑损伤。近年来的研究发现激活的小胶质细胞还能产生抗炎作用来加速脑损伤修复。因此,目前的研究将小胶质细胞分为促炎的M1型和抗炎的M2型。结合目前缺血性脑卒中的神经保护剂相对较少,靶向调控小胶质细胞的极化可能成为脑卒中新的治疗策略。研究发现中药能够通过抑制M1型小胶质细胞,并促进M2型的小胶质细胞来改善缺血性脑损伤,从而展现出对缺血性脑卒中的治疗潜力。本文综述了中药通过调节小胶质细胞极化表型来治疗脑卒中的相关研究,以期为缺血性脑卒中药物开发提供新的思路。     

中药通过调节小胶质细胞激活改善缺血性脑卒中（英文）

炎症反应是造成脑卒中继发性脑损伤的关键因素之一.小胶质细胞作为脑内免疫细胞,在脑卒中的炎症反应具有重要作用.传统观念认为小胶质细胞促进炎症反应加重脑损伤.近年来的研究发现,激活的小胶质细胞还能产生抗炎作用来加速脑损伤修复.因此,目前的研究将小胶质细胞分为促炎的M1型和抗炎的M2型.结合目前缺血性脑卒中的神经保护剂相对较少,靶向调控小胶质细胞的极化可能成为脑卒中新的治疗策略.研究发现中药能够通过抑制M1型小胶质细胞,并促进M2型的小胶质细胞来改善缺血性脑损伤,从而展现出对缺血性脑卒中的治疗潜力.本文综述中药通过调节小胶质细胞极化表型来治疗脑卒中的相关研究,以期为缺血性脑卒中药物开发提供新的思路.     

G-CSF 在缺血性脑卒中动物模型治疗中的研究进展

粒细胞集落刺激因子(G-CSF)是细胞生长因子家族中的一员,主要功能是刺激细胞增殖分化降低细胞凋亡。近年来许多缺血性脑卒中的实验研究显示其能有效改善由于脑卒中等中枢神经系统疾病所致的神经功能缺损,G-CSF用于缺血性脑卒中的治疗具有广阔的前景。文章从G-CSF在缺血性脑卒中的研究进展及其作用机制等方面进行综述。     

亲环素A:艾滋病治疗的潜在靶点

存在于宿主细胞质中的亲环素A(Cyclophilin A,CypA)对HIV-1的感染性具有重要影响。在病毒颗粒的脱壳过程中,CypA与衣壳蛋白的相互作用可破坏病毒衣壳的稳定性,加快病毒颗粒的解装配,并将病毒RNA释放出来进行逆转录,从而促进HIV-1的增殖。阻断CypA与衣壳蛋白的相互作用可以降低HIV-1的感染性,因此CypA极有可能成为抗HIV-1药物开发的新靶点。本综述主要介绍CypA的结构及功能,并对一些具有抗HIV-1活性的CypA抑制剂做一简要介绍。     

丁苯酞对缺血性脑卒中大鼠脂联素、MCP-1及slCAM-1的影响

目的:探讨丁苯酚对卒中大鼠脂联素、MCP-1和sl CAM-1表达的影响。方法:建立大鼠永久性大脑中动脉梗塞(Permanent middle cerebral occlusion, pMCAO)局灶性脑缺血模型,将SD大鼠分为Sham组、pMCAO模型组和NBP治疗组;甲酚紫染色法测定大鼠脑部梗塞面积;改良神经功能损害评分(Modified neurological severity score, m NSS)用于评定各组大鼠的神经功能变化情况;Elisa法检测大鼠脑部和血清中脂联素水平以及脑部MCP-1和sl CAM-1水平。结果:药物处理后pMCAO组大鼠存活率明显低于Sham组;NBP处理能够有效逆转pMCAO诱导的大鼠m NSS得分的升高;与Sham组相比,pMCAO组大鼠脑部梗塞面积显著增加,NBP处理明显减少了损伤大鼠的梗塞范围;与Sham组相比,p MCAO组大鼠脑部和血清中脂联素表达明显降低,而大脑MCP-1及sl CAM-1水平显著升高,NBP处理上调了大脑和血清脂联素的水平并抑制脑部MCP-1和sl CAM-1的表达。结论:丁苯酞通过上调脂联素表达,抑制MCP-1及sl CAM-1的水平对缺血性脑卒中大鼠起到神经保护作用。     

甲基苯丙胺对中枢神经系统炎症的影响及机制研究进展

甲基苯丙胺(methamphetamine, MA)滥用可严重损害中枢神经系统,但其机制尚未完全阐明,且缺乏有效治疗药物。MA滥用致中枢神经系统受损与小胶质细胞、星形胶质细胞、NF-κB、TNF-α、IL-6和IL-1β及其他一些与中枢神经系统炎症相关因子具有重要联系。现以甲基苯丙胺滥用和关键中枢神经系统炎症反应相关细胞、因子为关注点,重点阐述它们之间的关系,对该领域的研究进展进行综述。     

SOCS1在氯胺酮减轻小胶质细胞活化中的机制研究

目的:探讨麻醉药氯胺酮(Ketamine, KET)对暴露于脂多糖(Lipopolysaccharide, LPS)中的小胶质细胞活化水平的影响,并观察细胞因子信号转导抑制因子1(Suppressor of Cytokine Signaling 1, SOCS1)在其中的作用。方法:本研究选用N9小胶质细胞系,将其暴露于浓度为10 ng/mL的LPS中,模拟炎症反应,同时给与浓度为1 m M的KET,采用Western blot、酶联免疫吸附检测(Enzyme-Linked Immunosorbent Assay, ELISA)小RNA干扰和免疫细胞染色等方法,观察KET对暴露于LPS中的小胶质细胞活化水平的影响,及SOCS1分子在其中的作用。结果:将细胞分为3组,分别为正常培养的Control组、LPS组和KET+LPS组,研究发现,将N9小胶质细胞暴露于含10 ng/mL的细胞培养基中24 h后,细胞诱导型一氧化氮合酶(Inducible Nitric Oxide Synthase, i NOS)表达和培养基肿瘤坏死因子α(Tumor Necrosis Factorα, TNF-α)含量显著增加(P0.05),而KET可显著降i NOS蛋白表达和培养基TNF-α含量(P0.05)。随后,将细胞分为5组,分别为Control组、LPS组、KET+LPS组、SOCS1-siRNA+KET+LPS组和乱序siRNA(SC-siRNA)+KET+LPS组,我们发现,LPS可显著增加小胶质细胞TNF-α和白细胞介素1β(Interleukin-1β, IL-1β)的释放、增加SOCS1和核因子κB(Neuclear FactorκB, NF-κB)表达(P0.05),而KET可显著逆转LPS对炎症因子释放和NF-κB表达的影响,并进一步增加SOCS1表达(P0.05),而SOCS1-siRNA显著逆转了KET的上述作用(P0.05),SC-siRNA未对KET产生的上述作用造成显著影响(P0.05)。结论:KET可降低LPS对小胶质细胞的活化作用,上述作用可能通过SOCS1分子介导。     

创伤性脑损伤后IL-1?茁在神经胶质细胞中经时定位表达的研究*

目的:探讨创伤性脑损伤(TBI)后白细胞介素-1β(IL-1β)在神经胶质细胞中的经时定位表达情况。方法:选择72只SPF级雄性小鼠分为假手术组(sham组)、TBI 6h组、TBI 12h组、TBI 1d组、TBI 4d组与TBI 7d组,每组12只,分别在脑损伤后6h、12h、1d、4d、7d时获取血清和脑组织并且制作切片。ELISA检测损伤后炎症因子IL-1β、白细胞介素-6 (IL-6)和肿瘤坏死因子-α(TNF-α)的表达。Western blot检测钙离子结合蛋白-1(IBA-1)和胶质纤维酸性蛋白(GFAP)的表达。应用免疫荧光双重染色技术观察炎症因子IL-1β在小胶质细胞和星形胶质细胞中的定位表达情况。结果:TBI后6h-7d时炎症因子IL-1β、IL-6和TNF-α的表达量均高于sham组(P0.05)。Western blot结果显示,IBA-1的表达在损伤后6h-7d时高于sham组,GFAP的表达在损伤后1d-7d时高于sham组(P0.05)。免疫荧光双重染色技术显示,6h、12h时IL-1β主要表达在小胶质细胞中,IL-1β和IBA-1共表达细胞数量多于sham组(P0.05);1d、4d、7d时IL-1β主要表达在星形胶质细胞中,IL-1β和GFAP共表达细胞数量多于sham组(P0.05)。结论:TBI诱导了胶质细胞和炎症因子的表达,其表达随脑损伤的时间而变化,IL-1β早期定位表达于小胶质细胞,后期定位表达于星形胶质细胞中。     

功能化外泌体载人参皂苷Rg1治疗缺血性脑卒中

本研究旨在探讨c(RGDyK)肽修饰的骨髓间充质干细胞外泌体作为一种多功能载体材料负载人参皂苷Rg1 (ginsenoside Rg1, G-Rg1)对缺血性脑卒中的治疗效果和潜在作用机制。以线栓法制备SD大鼠短暂性大脑中动脉缺血性模型(transient middle cerebral occlusion model, tMCAO),并将造模成功的SD大鼠随机分为tMCAO组、Exo组、游离G-Rg1组、Exo-Rg1组和cRGD-Exo-Rg1组,并以sham组作为对照。采用2,3,5-三苯基四氯化铵(2,3,5-triphenyltetrachloride, TTC)染色法检测脑梗死体积;免疫荧光法观察神经元、血管内皮细胞数量变化;Western blotting实验检测相关蛋白的表达。结果表明cRGD-Exo-Rg1可通过激活PI3K/AKT通路上调血管内皮生长因子(vascular endothelial growth factor, VEGF)和缺氧诱导因子(hypoxia-inducible factors, HIF-1α)的表达,促进血管生成和神经生成,有效减少脑梗死体...     

Upregulation of Microglial ZEB1 Ameliorates Brain Damage after Acute Ischemic Stroke

1. Download high-res image (285KB)
2. Download full-size image

     

Age and the Metabolic Syndrome as Risk Factors for Ischemic Stroke: Improving Preclinical Models of Ischemic Stroke

Ischemic stroke represents a leading cause of morbidity and mortality in thedeveloped world. This disabling and sometimes fatal event puts an everincreasing burden on the family members and medical professionals who care forstroke victims. Preclinical ischemic stroke research has predominantly utilizedyoung adult, healthy animals, a clear discrepancy when considering the clinicalpopulation affected by stroke. A broad spectrum of risk factors such as age,obesity, diabetes, and hypertension has been associated with an increased strokerisk. The effect of these comorbidities on both stroke pathophysiology andoutcome has not been emphasized and has been recognized as a shortcoming ofpreclinical studies. By addressing these conditions in experimental models ofischemic stroke, it may be possible to more accurately represent the clinicalscenario and improve therapeutic translation from bench-to-bedside. In thiswork, we review many of the risk factors associated with increased stroke risk,particularly as each risk factor relates to inflammation. Additionally, weexplore potential animal models that could be utilized in identifying thecontribution of these risk factors to stroke outcome. By investigating the riskfactors for stroke and how these may alter stroke pathophysiology, the presentdiscrepancies between preclinical studies and the clinical reality can bereconciled in an effort to improve therapeutic development and translation frombench-to-bedside.     

The Effect of Annexin A1 as a Potential New Therapeutic Target on Neuronal Damage by Activated Microglia

Brain disease is known to cause irrevocable and fatal loss of biological function once damaged. One of various causes of its development is damage to neuron cells caused by hyperactivated microglia, which function as immune cells in brain. Among the genes expressed in microglia stimulated by various antigens, annexin A1 (ANXA1) is expressed in the early phase of the inflammatory response and plays an important role in controlling the immune response. In this study, we assessed whether ANXA1 can be a therapeutic target gene for the initial reduction of the immune response induced by microglia to minimize neuronal damage. To address this, mouse-origin microglial cells were stimulated to mimic an immune response by lipopolysaccharide (LPS) treatment. The LPS treatment caused activation of ANXA1 gene and expression of inflammatory cytokines. To assess the biological function in microglia by the downregulation of ANXA1 gene, cells were treated with short hairpin RNA-ANXA1. Downregulated ANXA1 affected the function of mitochondria in the microglia and showed reduced neuronal damage when compared to the control group in the co-culture system. Taken together, our results showed that ANXA1 could be used as a potential therapeutic target for inflammation-related neurodegenerative diseases.     

Anticoagulation for the Acute Management of Ischemic Stroke

Few prospective studies support the use of anticoagulation during the acute phase of ischemic stroke, though observational data suggest a role in certain populations. Depending on the mechanism of stroke, systemic anticoagulation may prevent recurrent cerebral infarction, but concomitantly carries a risk of hemorrhagic transformation. In this article, we describe a case where anticoagulation shows promise for ischemic stroke and review the evidence that has discredited its use in some circumstances while showing its potential in others.     

WIP1 Phosphatase as a Potential Therapeutic Target in Neuroblastoma

The wild-type p53-induced phosphatase 1 (WIP1) is a serine/threonine phosphatase that negatively regulates multiple proteins involved in DNA damage response including p53, CHK2, Histone H2AX, and ATM, and it has been shown to be overexpressed or amplified in human cancers including breast and ovarian cancers. We examined WIP1 mRNA levels across multiple tumor types and found the highest levels in breast cancer, leukemia, medulloblastoma and neuroblastoma. Neuroblastoma is an exclusively TP53 wild type tumor at diagnosis and inhibition of p53 is required for tumorigenesis. Neuroblastomas in particular have previously been shown to have 17q amplification, harboring the WIP1 (PPM1D) gene and associated with poor clinical outcome. We therefore sought to determine whether inhibiting WIP1 with a selective antagonist, GSK2830371, can attenuate neuroblastoma cell growth through reactivation of p53 mediated tumor suppression. Neuroblastoma cell lines with wild-type TP53 alleles were highly sensitive to GSK2830371 treatment, while cell lines with mutant TP53 were resistant to GSK2830371. The majority of tested neuroblastoma cell lines with copy number gains of the PPM1D locus were also TP53 wild-type and sensitive to GSK2830371A; in contrast cell lines with no copy gain of PPM1D were mixed in their sensitivity to WIP1 inhibition, with the primary determinant being TP53 mutational status. Since WIP1 is involved in the cellular response to DNA damage and drugs used in neuroblastoma treatment induce apoptosis through DNA damage, we sought to determine whether GSK2830371 could act synergistically with standard of care chemotherapeutics. Treatment of wild-type TP53 neuroblastoma cell lines with both GSK2830371 and either doxorubicin or carboplatin resulted in enhanced cell death, mediated through caspase 3/7 induction, as compared to either agent alone. Our data suggests that WIP1 inhibition represents a novel therapeutic approach to neuroblastoma that could be integrated with current chemotherapeutic approaches.     

CCR5 Is a Therapeutic Target for Recovery after Stroke and Traumatic Brain Injury

1. Download high-res image (162KB)
2. Download full-size image

     

The Neuroprotective Effects of Coccomyxa Gloeobotrydiformis on the Ischemic Stroke in a Rat Model

Stroke is a major cause of mortality and the leading cause of permanent disability. In this study, we adopted the classic middle cerebral artery occlusion(MCAO) stroke model to observe the therapeutic effects of coccomyxa gloeobotrydiformis(CGD) on ischemic stroke, and discuss the underlying mechanisms. Low dose (50 mg/kg.day) and high dose (100 mg/kg.day) concentrations of the drug CGD were intragastrically administrated separately for 8 weeks. Infarct volumes, neurologic deficits and degree of stroke-induced brain edema were measured 24 hours after reperfusion. Furthermore, oxidative stress related factors (SOD and MDA), mitochondrial membrane potential, and apoptosis regulatory factors (mitochondrial Cyt-C, Bcl-2, Bax, and caspase-3) were all investigated in this research. We found that CGD attenuated cerebral infarction, brain edema and neurologic deficits; CGD maintained the mitochondrial membrane potential and decreased mitochondrial swelling. It also prevented oxidative damage by reducing MDA and increasing SOD. In addition, CGD could effectively attenuate apoptosis by restoring the level of mitochondrial Cyt C and regulating the expression of Bcl-2, Bax and caspase 3. These results revealed that CGD has a therapeutic effect on ischemic stroke, possibly by inducing mitochondrial protection and anti-apoptotic mechanisms.     

Resolvin D1 reprograms energy metabolism to promote microglia to phagocytize neutrophils after ischemic stroke

1. Download : Download high-res image (265KB)
2. Download : Download full-size image